Atlas Trials

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Clinical trial NCT02665650 · COMPLETED

Trial details

NCT number
NCT02665650
Sponsor
Affimed GmbH
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hodgkin Lymphoma
Start date
2016-05-01
Primary completion
2019-01-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.